Ideaya Biosciences Announced Clinical Program Updates For IDE397, Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Ideaya Biosciences announced updates for its IDE397 Phase 2 clinical program targeting MTAP-deletion solid tumors. The program includes expansion in bladder and squamous lung cancer, with data expected in H2 2024. Over 35 clinical trial sites have been activated globally.
June 24, 2024 | 10:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ideaya Biosciences announced significant updates for its IDE397 Phase 2 clinical program, including expansion in bladder and squamous lung cancer. Data is expected in H2 2024, and over 35 clinical trial sites have been activated globally.
The expansion of the IDE397 Phase 2 program and the activation of over 35 clinical trial sites globally indicate a strong commitment to advancing this treatment. The expected data in H2 2024 could provide significant insights into the drug's efficacy, potentially driving investor interest and positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100